Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

US Revenue

US Revenue % Chg.

US Revenue Common Size

Japan Revenue

Japan Revenue % Chg.

Japan Revenue Common Size

Europe and Rest of World Revenue

Europe and Rest of World Revenue % Chg.

Europe and Rest of World Revenue Common Size

Total International Revenue

Total International Revenue % Chg.

Total International Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

ARIKAYCE Revenue

ARIKAYCE Revenue % Chg.

ARIKAYCE Revenue Common Size

BRINSUPRI Revenue

BRINSUPRI Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
ARIKAYCE Revenue	114.3	—
BRINSUPRI Revenue	28.1	—
Total Revenue	142.3	107.4

Revenue by Geography	Sep '25	Jun '25
US Revenue	102	68.7
Japan Revenue	—	30.7
Europe and Rest of World Revenue	—	8.1
Total International Revenue	40.3	38.7
Total Revenue by Geography	142.3	107.4